Key insight: PD-L1, a molecular target of cancer immunotherapy, is so closely tied to pain in animal experiments, scientists think it may mean the more pain is felt, the better the treatment is working.

Pain exists for a reason: It alerts us that something’s gone awry in our bodies. Now, a new study suggests that some cancers might block our ability to sense the pain that radiates from a tumor —allowing it to continue growing, surreptitiously.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Yep. As if people with cancer haven’t been manipulated, conned, and taken advantage of physically, emotionally and financially enough. Always another entity looking for what money you have left. Disgusting!

  • Since this is for subscription only readers, is there at least a reference to a journal article we can read for more information? Please!

  • Wow. Pretending to be an accessible article on the Globe main page and then demanding we subscribe to something completely separate from the Globe if we want to see it? Dirty trick.

  • Why masquerade as a Globe article and then not let people read the it? Hint: don’t go out of your way to look like you have your hand out for our hard earned dollars before you show you’re worth it. Right now, that would be a nope.

    • Trick articles are a good way to reduce STAT subscribers. I have to wade thru enough crap; not doing it here

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy